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Abstract
Despite the introduction of conjugated polysaccharide vaccines for many of the Neisseria meningitidis serogroups, neisserial
infections continue to cause septicaemia and meningitis across the world. This is in part due to the difficulties in developing
a, cross-protective vaccine that is effective against all serogroups, including serogroup B meningococci. Although
convalescent N. meningitidis patients develop a natural long-lasting cross-protective immunity, the antigens that mediate
this response remain unknown. To help define the target of this protective immunity we identified the proteins recognized
by IgG in sera from meningococcal patients by a combination of 2D protein gels, western blots and mass spectrometry.
Although a number of outer membrane antigens were identified the majority of the antigens were cytoplasmic, with roles
in cellular processes and metabolism. When recombinant proteins were expressed and used to raise sera in mice, none of
the antigens elicited a positive SBA result, however flow cytometry did demonstrate that some, including the ribosomal
protein, RplY were localised to the neisserial cell surface.
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Introduction
Neisseria meningitidis infection continues to cause considerable
disability and mortality throughout the world. Although polysac-
charide conjugate vaccines have been developed and used
successfully against many of the serogroups of N. meningitidis, such
a strategy has proved ineffective against group B meningococci.
This serogroup now represents the majority of cases in the UK [1].
Vaccines containing Outer Membrane Vesicle preparations
(OMVs) have been used to successfully to vaccinate against
specific outbreak strains of group B N. meningitidis [2,3,4], but such
preparations do not give sufficient cross protection to justify their
use as universal meningococcal vaccines. Although protein
antigens that are protective against serogroup B meningococci
have been identified by reverse vaccinology [5] there remains a
need to characterise the immune response to neisserial infection
and to identify further vaccine candidates for use in a cross
protective vaccine.
Classic studies performed in the 1960’s demonstrated the
importance of bactericidal antibody for protection against
meningococcal disease, as reviewed by Pollard and Frasch [6].
Several lines of evidence suggest that important and pan-reactive
determinants of immunity remain to be discovered. (i) In
immunocompetent individuals a single episode of meningococ-
caemia confers permanent immunity to all types of meningococci
[6,7,8]. (ii) Carriage of commensal species such as Neisseria lactamica
provides immunity to meningococcal disease [6,7,8]. (iii) Inocu-
lation of mice with attenuated mutant meningococcal strains
induces cross-reactive immune responses [9]. These findings
indicate that natural exposure (to either N. meningitidis or N.
lactamica) can provide long-term, cross-reactive protection, how-
ever the identity of the antigens involved remains unknown. They
are unlikely to be the well characterised class 1, 2 and 5 Outer
Membrane Proteins (OMPs) since these antigens do not induce a
cross-reactive bactericidal immune responses in immunized
volunteers [10].
The proteome of both the serogroup B strain, MC58 [11],
and the serogroup A strain, Z4970 [12], as well as the
composition of OMV preparations from both N. meningitidis
[13,14,15,16,17] and N. lactamica [13,14,17] have been cata-
logued using a combination of 2D SDS-PAGE gels and mass
spectrometry (reviewed by Wheeler et al. [18]). However, the
proteome itself does not provide information as to which proteins
are immunogenic. By combining proteomics with immunoblot-
ting it is possible to generate an immunoproteome that
catalogues those proteins that are recognized by the host
immune response. This immunoproteomics approach has been
applied to a wide of range of organisms including M. tuberculosis
[19], Streptococcus pneumonia [20], Staphylococcus epidermidis [21] and
Candida albicans [22]. In many cases this has led to the
identification of novel antigens that have been demonstrated to
be protective in animal models [20,21,22]. We here, apply
immunoproteomic approaches to N. meningitidis to identify
proteins that bind IgG from acute and convalescent meningo-
coccal patient’s sera with the aim of further understanding the
immune response to neisserial infection and to potentially
identify new cross-protective neisserial antigens.
Results
2D electrophoresis and Western blots
Proteins extracted from N. meningitidis L91543 were separated by
2D gel electrophoresis and western blotted with sera from acute
and convalescent patients (Table 1). Up to 473 separate protein
spots could be distinguished on the 2D gels (Fig 1). Eighty eight of
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5940Figure 1. 2D gels of total N. meningitidis proteins. Total N. meningitidis proteins separated by 2D gel electrophoresis using (a) a non-linear pI 4–7
1
st dimension and (b) a non-linear pI 6–9 1
st dimension. Gels were silver stained and replica gels western blotted with patient sera. Spots that were
recognised by one or more sera on western blots are circled. Spots whose identity was determined are numbered in black, those that remain
unidentified in grey.
doi:10.1371/journal.pone.0005940.g001
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patient sera to be detected on western blots (Fig 2).
Comparison of western blots immunoprobed with different
patient sera demonstrated clear differences in immune recognition
with individual patient serum recognising between one and 41
protein spots (Table 2). Many proteins were recognized by several
sera while others were specific to a single serum sample. As
expected, all the acute sera bound to fewer spots than their paired
convalescent sera. Unfortunately there was insufficient patient
information to attempt to relate immunogenic profiles to patient
details. No correlation to the infecting strain serotypes was
apparent, nor was there any obvious correlation to SBA titres
(most of the acute sera had high levels of complement independent
killing so an SBA titre could not be obtained). Replicate western
blots identified similar spot patterns.
Although 2D gels of OMVs clearly had different protein profiles
to gels with total protein preparations, no novel antigens were
identified when they were western blotted with the three mixed
convalescent sera (Table 2).
Identification of antigens
Immunogenic proteins were excised from the gels and identified
by mass spectrometry. Of the 88 spots that were detected on the
western blots, 54 were successfully identified by mass spectrom-
etry, representing 33 different proteins (Table 2, Table S1). Many
of the proteins were identified from more than one spot, often with
the same molecular weight but with differing pI values.
Presumably, these represent isoforms of the same protein that
retain their immunogenicity. Some of these isoforms appear to be
immunologically distinct from each other. For instance spots 105
and 106, both identified as SucC were recognized by IgG in
convalescent sera from patient 1, however the spot adjacent to 106
that was also identified as SucC, but did not bind IgG (Fig 1).
The immunogenic proteins identified (Table 2) represent a wide
range of functions, including chaperones, ribosomal proteins and
many that are involved in central metabolism. Most of these
proteins are predicted to be cytoplasmic and therefore are not
expected to be directly accessible to the immune system in intact
cells. This was despite the presence of many of the established
outer membrane antigenic proteins such as PorA, PorB, Opa, and
RmpM on the 2D gels.
Cloning, Expression and Confirmation of antigens
Genes encoding the protein antigens were PCR amplified and
cloned into the expression vector, pET101. Eighty two percent of
the proteins were successfully expressed. Most of these recombi-
nant proteins were demonstrated, by western blotting, to bind the
patient sera with which they were originally identified (Table 3),
confirming that the mass spectrometry identification was correct.
Of those tested only the putative nucleotidase NMB2015, 50S
Figure 2. An example western blot of a 2D gel of total protein. Total N. meningitidis proteins separated by 2D gel electrophoresis using a non-
linear pI 4–7 1
st dimension, western blotted, and probed with convalescent sera from patient 3. Spots that were assigned protein identities are
indicated. Spots with no protein legend have not been identified. Longer exposures of this blot revealed more spots (Table 2).
doi:10.1371/journal.pone.0005940.g002
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transferase, NMB0631, did not bind the original patient sera
indicating that either the wrong spot was picked from the 2D gels,
that the protein was mis-identified or that the recombinant protein
has lost the epitopes that were present on the native protein.
ELISAs with recombinant proteins and cell lysates
Recombinant proteins were used to raise sera in mice. All of the
sera gave ELISA titers of .1:10,000 against recombinant protein
except for FtsZ which had a titer of 1:80. In ELISAs with cells that
had been heat killed and sonicated, all of the sera except for FtsZ,
PilT-2, Adk, AcnB and HisD recognized antigens from the
meningococcal cells, indicating that they were present in amounts
and in a conformation that could be recognized by the sera raised
against the recombinant protein.
Serum Bactericidal Assays
None of the successfully expressed antigens identified in this
study gave a positive SBA of $1:4. Control assays using OMVs
and recombinant fHBP consistently gave titres .1:512. No killing
was seen in control wells lacking either active complement, sera, or
both.
Flow cytometry
The subcellular location of antigenic proteins was investigated
by flow cytometry. Sera raised against the meningococcal surface
protein, fHBP was used as a positive control (Fig 3a), while sera
raised in mice immunised with PBS was used as a negative control.
Several of the recombinant proteins raised IgG that bound to the
surface of whole, live cells. RplY was clearly available on the
surface, with a significant shift in the fluorescence of the entire
population (p=0.001) (Fig 3b). Sera raised against RmpM, CysK
and AcnB also showed small but significant shifts in fluorescence of
the total population as well as a small but significant subpopulation
of cells with relatively high levels of fluorescence (Fig 3). The
subpopulations with high fluorescence had similar side scatter and
forward scatter profiles to the whole population indicating that the
cells were intact.
Discussion
Our aim in this study was to begin to characterize the
meningococcal immunoproteome and possibly to identify novel
antigens that are the targets of natural cross-protective immunity.
By using a combination of 2D gels, western blots and proteomics,
we identified a set of proteins that were recognized by sera from
both acute and convalescent patients suffering from meningococ-
cal septicaemia. This approach contrasts with previous studies
aimed at identifying naturally occurring immunological responses
such as Litt et al. [47], in that preconceived criteria, such as in silico
predications of protein function, were not applied.
Both the number and identity of the proteins identified by each
sera varied considerable. No antigen was recognized by all the sera
and several antigens were recognised by only a small number of
patient serum samples. The origin of this diversity of immune
response is currently unknown. It is possible it represents innate
differences in immunological responsiveness to the antigens, or
variations in antigenic exposure in different patients due to
variations in treatment timings or disease severity.
The antigens that were identified are a diverse group of
proteins, ranging from known outer membrane proteins such as
RmpM, to enzymes of central metabolism and ribosomal proteins
(Table 2). Where possible the immunogenicity of the identified
proteins was confirmed by cloning, protein expression and by
demonstrating that the recombinant proteins were recognized by
patient sera (Table 3). Many of the proteins are predicted to be
located in the cytoplasm or inner membrane of the meningococcus
and so were not considered by Litt et al. [47] in their screen of
immunological responses to infection. Other studies that have used
similar 2D gel/western blot approaches to identify antigens have
been undertaken using a range of organisms including Helicobacter
pylori [30] Chlamydia trachomatis [25], Borrelia burgdorferi [37], and
Mycobacteria tuberculosis [19]. These have also generated lists of
antigenic proteins that contain large numbers of proteins with a
cytosolic function. For instance, DnaK, CysK, FumB and AtpA
have all been identified from Brucella abortus as immunoreactive by
Connolly et al. [42], while TufA, DnaK and RpsA have been
identified as immunoreactive in Chlamydia trachomatis [25]. The
most obvious explanation for these immune responses is that they
are generated during episodes of septicaemia when killed
meningococcal cells release their cytoplasmic contents into the
circulation. Such a scenario would suggest that although these
antigens may be involved in the immune response to septicaemic
meningococcal disease, they are unlikely to be good vaccine
candidates.
However, we have demonstrated that several of these
‘‘cytoplasmic’’ proteins were present on the surface of neisserial
cells and so may be involved in immune responses that are
relevant to live meningococcal cells. The presence of neisserial
‘‘cytoplasmic’’ proteins on the surface has been reported
previously, for example Ferrari et al. [48] found enolase, Hsp60,
TufA and glyceraldehyde 3-phosphate dehydrogenase on the
neisserial surface by flow cytometry while other researchers have
identified RplL [23,24], DnaK [41], and LpdA2 [45] as being
surface exposed. The flow cytometry data presented here
Table 1. Details of patient sera.
Patient Strain Patient History
1 C:NT:P1.5,2 Severe septicaemia
2n d
a Mild septicaemia
3 B Not known
4n d
a Severe septicaemia
5 B Severe septicaemia
6 B Mild septicaemia
7 B:4:P1.4 Not known
8 B:4:NT Not known
9 B:4:NT Not known
10 B:NT:P1.9 Not known
11 B:4:P1.4 Not known
12 B:4:P1.4 Not known
13 B:15:P1.7,16 Not known
14 B:4:P1.4 Not known
15 B:4:P1.4 Not known
16 B:4:P1.4 Not known
17 C Not known
18 C Not known
19 C Not known
20 W135 Not known
21 Y Not known
doi:10.1371/journal.pone.0005940.t001
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the cell surface with levels of fluorescence comparable to those
found with recognised surface antigens such as NMB1468 [49],
NMB2132 and NMB2091 [5], although considerably lower than
other surface antigens such as fHBP [5]. A different pattern of
surface localization was found for CysK and AcnB, were flow
cytometry indicated that the proteins were surface exposed at
relatively high amounts but only in a subpopulation of cells.
Similar results were obtained in these experiments with RmpM, a
known outer membrane protein. Such heterogeneity in surface
expression has been found with several proteins in Streptococcus
pneumoniae and has been attributed to variation in capsule
morphology [50]. As we used a capsulated strain it is possible
that variations in meningococcal capsule morphology may
similarly expose meningococcal antigens to recognition by the
host immune response in a proportion of the neisserial population.
Alternatively, surface exposure of these proteins may be transient,
only occurring during specific phase of the meningococcal cell
cycle, or be subject to phase variation.
None of the identified immunogenic proteins generated murine
immune sera with bactericidal activity. For those proteins not
expressed on the surface it is likely that the absence of SBA activity
is due to lack of accessibility of antibody to the antigens. For those
proteins with either low or transient surface expression it seems
likely that either the level of antigen on the surface is insufficient to
promote bactericidal killing or, for transiently expressed proteins,
only a fraction of the population may be killed. Such proteins
would be missed by the current bactericidal assays.
These data represent the first proteome wide investigation of the
naturally induced immune response to neisserial infection with
implications for the understanding of the immune response to
septicaemic infection. The antigens identified demonstrate that
meningococcal patients have highly variable immune responses
against a wide range of meningococcal antigens. All the sera tested
contain antibodies capable of binding a range of neisserial
proteins, including many ‘‘cytoplasmic’’ proteins, some of which
are for the first time shown to be available to IgG on the surface of
whole neisserial cells. Although not sufficient to promote
detectable complement mediated killing, immune responses
against these antigens may still be involved in the pathogenesis
and immunity to meningococcal disease.
Materials and Methods
Protein preparation
Neisseria meningitidis L91543 was used thoughout (obtained from
the Manchester Public Health Laboratory, UK), this is a group
C:2a:P1.2, and part of the ST-11, ET-37 complexes. Although
such a serogroup C strain is not suited to the identification of
vaccine antigens aimed at serogroup B Neisseria, it is applicable for
the identification of the cross reactive antigens which this study
aimed to discover. Protein for 2D gels was prepared from cultures
grown for 4 h on Columbia Agar Base supplemented with 6%
horse blood (CAB) at 37uC with 5% CO2. Cells were washed in
PBS and proteins prepared using a ProteoPrepH Sample
Extraction Kit (Sigma). Cells were resuspended in Reagent 4
and sonicated for 10 min. The cells were centrifuged for 5 min
and the pellet discarded, freshly prepared Tributylphosphine
(TBP) was added to the supernatant, and the mixture incubated
for 1 h at room temperature. The proteins were alkylated with
iodoacetamide (IAA) for 1.5 h at room temperature. OMVs were
prepared using sodium deoxycholate from 4 h old CAB plate
cultures according to Fredriksen et al. [51].
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PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e5940Table 3. Proteins that bound IgG from one or more of the patients sera.
NMB Name Protein Confirmed
a Literature
0052 Pilin retraction protein PilT-1 nd
0131 50S ribosomal protein L7/L12 RplL Y Evidence for a surface role in N. gonorrhoeae during cell invasion [23,24]
Immunoreactive in Chlamydia trachomatis [25]
Protective against Brucella abortus in mouse model [26]
Neisserial L7/12 shown to be immunogenic but with limited immunogenicity for T cells
[27]
Identified on the surface of Streptococcus oralis [28]
0138 Elongation factor G FusA Y Thermus thermophilus elongation factor G shown to be putatively membrane
associated [29]
Proposed as a diagnostic antigen in Helicobacter pylori [30].
Identified on the surface of Streptococcus oralis [28]
0139 Elongation factor Tu TufA Y Fibronectin binding in Mycoplasma pneumoniae [31]
Cell wall associated in Mycobacteria leprae [32]
Surface associated and associated with cell adhesion in Lactobacillus johnsonii [33]
Bovine IgG binds Ef-Tu on surface of Anaplasma marginale [34]
Surface located virulence factor on Pseudomonas aeruginosa, binding factor H and
plasminogen [35]
Immunoreactive in Chlamydia trachomatis [25].
0143 50S ribosomal protein L4 RplD N
0336 Enoyl reductase FabI Y
0382 OMP class 4 RmpM Y Well documented surface protein [36].
0427 FtsZ FtsZ Y Immunogen in convalescent Borrelia burgdorferi patients [37]
A structural homolog is antigenic in Bartonella bacilliformis [38]
0530 Beta-hexosaminidase NagZ nd
0546 Alcohol dehyrogenase AdhP nd Immuno-reactive in patients with systemic candidiasis [39]
0554 DnaK protein (hsp) DnaK nd Immunoreactive and partially protective in mouse model for Bruclla abortus [40]
Localized to the surface in Neisseria meningitidis [41]
Immunoreactive in Chlamydia trachomatis [25].
0574 Glycine cleavage system T protein GcvT Y
0631 Phosphate acetyltransferase Pta N
0671 Malate oxidoreductase SfcA Y Found in the immunoproteome of Brucella abortus [42]
Putative serodiagnostic with Mycobacterium tuberculosis [43]
0763 Cysteine synthase CysK Y Found in the immunoproteome of Brucella abortus [42]
0768 Pilin retraction protein PilT-2 Y
0823 Adenylate kinase Adk Y Identified on the surface of Streptococcus oralis [28]
0876 Ribosomal protein L25 RplY Y Antigens found in patients with borreliosis [44]
0959 Succinyl coA synthase SucC Y
1201 IMP dehydrogenase GuaB Y Immunoreactive and protective in mice infected with Candida albicans [22]
1301 30S ribosomal protein S1 RpsA Y Immunoreactive in Chlamydia trachomatis [25]
1344 OMP p64k, PDH, E3 component LpdA2 Y Outer membrane location in Neisseria [45]
Recognised by sera from convalescent neisserial patients [46]
1429 OMP PorA PorA nd Well documented OMP
1572 Aconitate hydratase 2 AcnB Y Immuno-reactive in patients with systemic candidiasis [39]
1581 Histidinol dehydrogenase HisD Y
1613 Fumarate hydrytase FumB nd Found in the immunoproteome of Brucella abortus [42]
1934 ATP synthase F1 beta chain AtpD Y
1972 Hsp60 GroEL Y Conserved proteins that are immunogenic in many bacterial pathogens
2002 Elongation Factor Ts Tsf nd Identified on the surface of Streptococcus oralis [28]
2015 Hypothetical - N
2155 e transfer flavoprotein, beta subunit EtfB nd
2156 Heptosyltransferase I RfaC nd
Immunity to Meningococcus
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Protein concentrations were determined using RC DC Protein
Assay (BioRad). ZoomH 1
st dimension strips (Invitrogen) were
rehydrated for 18 h with 20 mg protein in 155 ml rehydration
buffer (8 M urea, 2% CHAPS, 50 mM dithiothreitol (DTT), 0.5%
ZoomH carrier ampholytes of an appropriate pI range (GE
Healthcare), 0.002% bromophenol blue) and focused at 200 V for
15 min, 450 V for 15 min, 750 V for 15 min followed 2000 V for
140 min. Strips were alkylated with 1% DTT in equilibration
buffer (1.5 M Tris, 6 M urea, 30% glycerol, 2% SDS, 0.002%
bromophenol blue, pH 8.8) for 15 min, and then reduced with 4%
IAA in equilibration buffer for 15 min. Focused 1
st dimension
strips were loaded onto 2
nd dimension NuPAGEH Novex 4–12%
Bis-Tris ZOOMH gels (Invitrogen) and electrophoresed at 200 V
as recommended by the manufacturers. Gels were silver stained as
described by Mortz et al. [52].
Serum
Four pairs of acute and convalescent sera (patients 1, 2, 3 and
4); two single convalescent serum (patients 5 and 6) and three
samples of pooled serum, each containing five convalescent sera
(patients 7–11, 12–16, and 17–21), were used to probe 2D gels of
total neisserial proteins (Table 1). OMV preparations were only
probed with the three convalescent sera mixes.
Western blots
Replica 2D gels were western blotted onto PVDF membrane
(Roche). Blots were incubated in PBS containing 10% blocking
reagent (Roche) for 30 min at room temperature, and then with
patient sera at dilutions of between 1:100 and 1:500. Blots were
washed three times for 10 min each with PBS containing 0.1%
TweenH 20 (PBS-Tw), and then incubated with 1:10,000 dilution
of anti-human IgG conjugated with peroxidase (Sigma) for 30 min
at room temperature followed by three 10 min washes with PBS-
Tw. Blots were developed with CSPD (Roche) and exposed.
Developed films were overlain with replica silver stained 2D gels
and spots that aligned with spots on the western blot were
determined. These immunogenic spots were picked and washed
twice for 20 min each with 50% acetonitrile (ACN), 50% 400 mM
NH4HCO3 (ABC). Gel plugs were left in 100% ACN for 10 min
and then air dried. The plugs were incubated in 10 mM DTT in
50 mM ABC for 30 min at 60uC followed by 30 min at room
temperature in the dark with 100 mM IAA in 100 mM ABC. The
gel plugs were again washed twice in 50% ACN, 50% 400 mM
ABC and again incubated for 10 min in 100% ACN and air dried.
The pellet was digested for 3 h with 50 ng trypsin (Promega) in
5 ml 10 mM ABC.
Mass spectrometry
Proteins were identified by Matrix-assisted laser desorption
time of flight mass spectrometry (MALDI-TOF) using a Bruker
AutoflexH machine. Matrix solutions were freshly prepared by
dissolving a-cyano-a-hydroxycinnamic acid (a-CCA) in acetone
to saturation and spotted onto either a stainless steel or
AnchorChip
TM target plates and allowed to dry. A 0.5 ml drop
of trypsin digested sample was placed on the matrix and the
peptides allowed to adsorb for 1–2 min before being removed
and the samples washed with 10% formic acid. Mass spectra
were acquired with between 300–1200 laser pulses in positive
reflective mode with an acceleration voltage of 19 kV. Samples
were calibrated with Peptide Calibration Standard (Bruker). The
peptide masses were obtained from the spectra using XMASS
5.1 (Bruker) and used to search the neisserial proteins in the
NCBI database using MASCOT (Matrix Science) with search
criteria of 50 ppm error, fixed modifications of carbamidomethyl
modified cysteine residues, variable modifications of oxidised
methionines and allowing 1 missed trypsin cleavage. Protein
identities were considered reliable if the expected probability was
,0.05 (details of methods are available in Document S1 and
Table S2).
Cloning and expression
Proteins that had been identified by MALDI analysis were
cloned and expressed using the pET101-TOPO system (Invitro-
gen). Primers for the N and C terminals of the annotated ORFs
from N. meningitidis MC58 genome (http://cmr.tigr.org) were
used to PCR amplify products from L91543 genomic DNA
prepared according to Bjorvatin et al. [53]. PCR reactions
contained 10 mM Tris pH 8.8, 25 mM KCl, 5 mM (NH4)2SO4,
2 mM MgSO4, 0.2 mM primers, 0.02 U ml
21 Pwo (Roche) and
0.2 mM dNTPs. Cycle conditions were 94uC for 5 min, followed
by 35 cycles of 94uC for 30 sec, 58uC for 30 sec and 72uC for
2 min, followed by 5 min at 72uC. Products were mixed with
pET101-TOPO vector and transformed into TOP10 cells
(Invitrogen). The correct constructs were identified by PCR
and restriction digests, and the plasmids transformed in BL21
cells. The pET21b plasmid expressing factor H binding protein
(fHBP), NMB1870 was kindly supplied by Chris Tang (Imperial
College, London). Proteins were expressed by growing BL21
transformants to approximately OD600 0.6 and inducing with
IPTG to 1 mM. Cells were incubated for 3 h, the cultures
centrifuged and the pellet lysed by resuspending in BugBusterH
(Novagen) with 2 mgm l
21 DNase and 50 mgm l
21 lysozyme for
20 min. Lysates were centrifuged and the cleared supernatant
applied to a previously equilibrated HisSelect
TM (Sigma) column.
The column was washed with 50 mM NaPO4, pH 8, 0.3 M
NaCl, 5 mM imadazole and the proteins eluted with 50 mM
NaPO4, pH 8, 0.3 M NaCl, 250 mM imadazole. Proteins were
dialysed against 10006 volumes of PBS and quantified using a
2D Quant kit (Amersham).
Mouse Immunizations
Recombinant proteins were used to generate serum according
to Giuliani et al. [5]. Briefly, female, NIH mice were immunised
subcutaneously on days 0, 21 and 35 with 20 mg protein each,
initially with Freund’s complete adjuvant and subsequently with
NMB Name Protein Confirmed
a Literature
n/a Opa900(FAM18), not in MC58 n/a nd Well documented OMP
aRecombinant proteins that were confirmed as binding their identifying sera are indicated (Y), those that failed to bind their identifying sera are indicated (N) and those
that were not determined, either because no recombinant protein was generated or because no more sera was available are indicated (nd).
doi:10.1371/journal.pone.0005940.t003
Table 3. cont.
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the serum frozen. Animals were housed and cared for according to
UK Home Office codes of practice and experiments were
approved by the University of Surrey Ethics Committee.
ELISAs
For ELISAs with recombinant protein, 50 mlo f2mgm l
21 was
added to each Maxisorp
TM (Nunc) microtiter well and incubated
overnight at 4uC. For whole cell ELISAs, bacteria were grown for
Figure 3. Flow cytometry of live N. meningitidis stained with mouse sera immunised with recombinant proteins. Flow cytometry data
for live N. meningitidis cells stained with sera from mice immunised with PBS alone (black) or with recombinant proteins (grey), fHBP has been used as
a positive control (Fig 3a). Values are means of fluorescence with standard deviations derived from triplicate experiments.
doi:10.1371/journal.pone.0005940.g003
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adjusted to 0.05. Cells were heated at 56uC for 30 min, followed
by 5 min of sonication and 50 ml added to Maxisorp
TM ELISA
wells and dried. All plates were washed three times in PBS-Tw and
blocked for 90 min at 37uC with 50 ml PBS containing 10%
blocking agent (Roche). A serial dilution of serum in PBS with
10% blocking agent was added to the wells and the plates
incubated for 2 h at 37uC. Plates were washed three times with
PBS-Tw and anti-mouse IgG peroxidase conjugate (Sigma) diluted
1:10,000 in PBS with 10% blocking agent added. Plates were
incubated for 1 h in the dark at 37uC and washed three times in
PBS-Tw. Colour reagent, 3,39,5,59-Tetramethylbenzidine (TMB)
was dissolved in 0.05 M phosphate-citrate buffer, pH 5 containing
10% DMSO and added to each well, the colour was allowed to
develop and the reaction stopped by adding H2SO4 to 0.4 M. The
OD450 of each well was measured. Titres were determined as the
last dilution at which the OD450 was greater than 0.1 and more
than twice the value for the equivalent dilution containing negative
sera (from mice immunised with PBS alone).
Serum Bactericidal Assays
Serum Bactericidal Assays (SBAs) were carried out according to
Borrow and Carlone [54]. Briefly, N. meningitidis, L91543, grown
overnight on CAB were inoculated into Mueller Hinton broth to
an OD600 0.1, and shaken at 35uC for 4 h. Cultures were diluted
to OD600 0.1 and then diluted a further 1:5,000, 10 ml was added
to microtiter wells containing a 10 ml of a 1:4 dilution of baby
rabbit complement (Serotech, UK) and 20 ml of a twofold serial
dilution of heat denatured (56uC for 30 min) sera. Plates were
incubated for 1 h and samples plated onto CAB media. Each assay
included control wells with either no sera, heat inactivated
complement, or neither sera nor active complement. Positive
wells were those containing 50% of the number of cells in the
control wells. SBA results for recombinant proteins were
compared to sera from mice immunised with PBS alone, OMVs
(as a positive control for the SBA), and the known bactericidal
antigen fHBP (assayed with N. meningitidis MC58, as a positive
control for the recombinant protein production and immunization
protocols)
Flow Cytometry
N. meningitidis for flow cytometry were grown for 4 h on CAB,
resuspended in PBS and adjusted to an OD600 of 1. A 20 ml
volume of cells was centrifuged, the pellet resuspended in 10 ml
heat denatured sera and incubated for 30 min at 37uC. The cells
were washed three times in 100 ml PBS-Tw and resuspended in
100 ml 4% paraformaldehyde for 18 h at 4uC. Cells were washed
three time in 100 ml PBS-Tw and resuspended in 20 ml anti-mouse
IgG conjugated to FITC (Sigma) diluted 1:50 in PBS. Cells were
incubated for 30 min at room temperature in the dark, washed
three times in PBS-Tw and resuspended in 1 ml PBS. Fluores-
cence was measured with a BD FACSCanto
TM Flow Cytometer
recording 10,000 events and the data compared to samples
containing either no cells, or cells stained with sera from mice
immunised with fHBP, OMV preparations or PBS alone. Data
were analysed using WinMDI, recorded events were gated with
reference to the control samples and the population statistics
determined from triplicate experiments.
Supporting Information
Table S1 Mass Spectrometry Data
Found at: doi:10.1371/journal.pone.0005940.s001 (0.05 MB
XLS)
Table S2 MS exclusion list
Found at: doi:10.1371/journal.pone.0005940.s002 (0.03 MB
XLS)
Document S1 Parameters for MS data acquisition and database
searching
Found at: doi:10.1371/journal.pone.0005940.s003 (0.03 MB
DOC)
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